A recombinant modified vaccinia ankara vaccine encoding Epstein-Barr Virus (EBV) target antigens: a phase I trial in UK patients with EBV-positive cancer. [electronic resource]
Producer: 20150625Description: 5009-22 p. digitalISSN:- 1557-3265
- Adult
- Aged
- Cancer Vaccines -- administration & dosage
- Combined Modality Therapy
- Epitopes, T-Lymphocyte -- immunology
- Epstein-Barr Virus Infections -- complications
- Epstein-Barr Virus Nuclear Antigens -- genetics
- Female
- Herpesvirus 4, Human -- genetics
- Humans
- Immunophenotyping
- Lymphocyte Count
- Male
- Middle Aged
- Neoplasm Staging
- Neoplasms -- diagnosis
- T-Cell Antigen Receptor Specificity
- T-Lymphocyte Subsets -- immunology
- Treatment Outcome
- Vaccination
- Vaccinia virus -- genetics
- Viral Load
No physical items for this record
Publication Type: Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
There are no comments on this title.
Log in to your account to post a comment.